Culture
Elizabeth Holmes Pitching New Blood Test Company From Prison Cell
By BSN Staff, . BSN Network. Satire.
BRYAN, TX, Federal Correctional Institution, Bryan, Texas, Tuesday. Elizabeth Holmes, the founder and former CEO of Theranos who was convicted in 2022 of defrauding investors out of roughly nine hundred million dollars by claiming her company could run hundreds of medical tests from a single drop of blood, a claim that was entirely false, is reportedly already planning her next venture in the blood testing space.
She has not yet finished serving the first one.
According to three people who received the pitch deck and agreed to speak on condition of anonymity because they are still trying to figure out how they feel about it, the new company is called Luminos, is described as a "next-generation precision diagnostics platform," and requires a minimum investment of five hundred thousand dollars. The deck includes a headshot in which Holmes appears to be wearing a turtleneck that sources describe as "somehow prison-issue but somehow still black."
"Why would I deceive you? There's no reason for me to do that," Holmes reportedly told one prospective investor during a monitored phone call last month, deploying what legal analysts are calling the exact sentence a person who is actively deceiving you would say.
Former Theranos patients, some of whom received false cancer diagnoses or false all-clear results from technology that never worked, have had a range of reactions to the news. "I don't have words," said Carla Mendez of Phoenix, who in 2015 underwent a surgical procedure based on a Theranos result that turned out to be incorrect. She then paused for a long time and found several words.
Holmes, for her part, appears to have processed the trial, the conviction, the sentence, the documentary, the Hulu miniseries, the book, the podcast, the second podcast, and the general global consensus that she is one of the more brazen fraudsters in the history of American commerce, and emerged with the central takeaway that the market for blood diagnostics remains underserved.
This is, technically, not wrong. Theranos did identify a real problem. The problem was that they solved it by lying.
Luminos, according to the pitch deck, will be different. It will use "proprietary nano-assay architecture" and "AI-verified result chains" to deliver "clinically actionable insights from sub-milliliter samples." A scientist who reviewed the document at BSN's request said these phrases do not correspond to any existing technology and that two of them appear to have been assembled by feeding the phrase "blood testing" into a language model and asking it to sound expensive.
A spokesperson for the Federal Bureau of Prisons confirmed that inmates are permitted to engage in limited business correspondence but declined to comment on whether operating a startup from a federal corrections facility was specifically addressed in the inmate handbook. "We do not comment on individual inmates," the spokesperson said, which is the Bureau of Prisons' way of commenting on an individual inmate.
Investment analysts are divided. One partner at a Silicon Valley firm who asked not to be named said Holmes "still has the vision thing," then immediately asked to retract the quote. A second analyst said the only rational response was to "never speak to this reporter again" and hung up, which is a form of divided opinion.
Holmes is scheduled for release in 2032. The Luminos deck includes a projected launch date of Q3 2032.
She has already reserved the domain.
The story we are making fun of: https://nypost.com/2026/09/09/business/unrepentant-elizabeth-holmes-already-plotting-biotech-comeback-from-behind-bars/